Bifogade filer
Boule Diagnostics appoints Michael af Winklerfelt as new CFO
Kurs
-1,80%
Likviditet
1,91 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2027-02-10 | 08:00 | Bokslutskommuniké 2026 |
| 2026-10-23 | 08:00 | Kvartalsrapport 2026-Q3 |
| 2026-07-17 | 08:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-13 | N/A | Årsstämma |
| 2026-04-28 | 08:00 | Kvartalsrapport 2026-Q1 |
| 2026-02-11 | 08:00 | Bokslutskommuniké 2025 |
| 2025-10-24 | - | Kvartalsrapport 2025-Q3 |
| 2025-07-18 | - | Kvartalsrapport 2025-Q2 |
| 2025-04-29 | - | X-dag ordinarie utdelning BOUL 0.00 SEK |
| 2025-04-28 | - | Årsstämma |
| 2025-04-28 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-11 | - | Bokslutskommuniké 2024 |
| 2024-10-25 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-10 | - | X-dag ordinarie utdelning BOUL 0.00 SEK |
| 2024-05-08 | - | Årsstämma |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-06 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | X-dag ordinarie utdelning BOUL 0.00 SEK |
| 2023-05-04 | - | Årsstämma |
| 2023-05-03 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-02 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-11-01 | - | Extra Bolagsstämma 2022 |
| 2022-07-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning BOUL 0.55 SEK |
| 2022-05-05 | - | Årsstämma |
| 2022-05-04 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-03 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-07 | - | X-dag ordinarie utdelning BOUL 0.55 SEK |
| 2021-05-06 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-03 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-17 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-08 | - | X-dag ordinarie utdelning BOUL 0.00 SEK |
| 2020-05-07 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-07 | - | Bokslutskommuniké 2019 |
| 2019-10-30 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-14 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-07 | - | X-dag ordinarie utdelning BOUL 0.55 SEK |
| 2019-05-06 | - | Årsstämma |
| 2019-05-06 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-07 | - | Bokslutskommuniké 2018 |
| 2018-11-06 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-15 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-01 | - | Split BOUL 1:4 |
| 2018-05-15 | - | X-dag ordinarie utdelning BOUL 2.00 SEK |
| 2018-05-14 | - | Årsstämma |
| 2018-05-14 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-16 | - | Bokslutskommuniké 2017 |
| 2017-11-08 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-12 | - | X-dag ordinarie utdelning BOUL 1.40 SEK |
| 2017-05-11 | - | Årsstämma |
| 2017-05-11 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-11-09 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-31 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-13 | - | X-dag ordinarie utdelning BOUL 0.60 SEK |
| 2016-05-12 | - | Årsstämma |
| 2016-05-12 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-11-04 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-24 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-13 | - | X-dag ordinarie utdelning BOUL 0.60 SEK |
| 2015-05-12 | - | Årsstämma |
| 2015-05-12 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-13 | - | Bokslutskommuniké 2014 |
| 2014-11-05 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-28 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-14 | - | X-dag ordinarie utdelning BOUL 0.50 SEK |
| 2014-05-13 | - | Årsstämma |
| 2014-05-13 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-07 | - | Bokslutskommuniké 2013 |
| 2013-10-30 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-21 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-24 | - | X-dag ordinarie utdelning BOUL 0.50 SEK |
| 2013-04-23 | - | Årsstämma |
| 2013-04-23 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-13 | - | 15-7 2013 |
| 2013-02-19 | - | Bokslutskommuniké 2012 |
| 2012-11-09 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-30 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-14 | - | Kapitalmarknadsdag 2012 |
| 2012-05-04 | - | X-dag ordinarie utdelning BOUL 0.00 SEK |
| 2012-05-03 | - | Årsstämma |
| 2012-04-26 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-21 | - | Bokslutskommuniké 2011 |
| 2011-11-29 | - | 15-7 2011 |
| 2011-11-11 | - | Kvartalsrapport 2011-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Boule Diagnostics AB appoints Michael af Winklerfelt as new CFO, effective February 2026. Michael af Winklerfelt brings extensive international experience from senior finance roles in pharmaceuticals, medical technology, and industrial sectors. He has served as CFO in several listed companies, overseeing finance, IT, HR, and investor relations. Michael has successfully led capital raisings, IPO processes, and strategic restructurings, strengthening Boule’s position and future opportunities. Previous roles include CFO at Fresenius Kabi Sweden AB, XSpray Pharma AB, Prostatype Genomics AB, and Oasmia AB, as well as senior finance positions within the Atlas Copco Group. He holds an MBA from Emory University and an MSc from the Stockholm School of Economics.
“We are delighted to welcome Michael as Boule’s new CFO. His strong financial expertise and broad experience across commercial and operational areas will be crucial in driving Boule’s global growth, improving profitability, and delivering innovation in decentralized blood diagnostics,” says Torben Nielsen, President and CEO.
Current CFO Holger Lembrér will remain in his role until Michael af Winklerfelt assumes the position in February 2026.
Contacts
Torben Nielsen, CEO and Group President, torben.nielsen@boule.com, phone +46 (0)70-558 51 05
About Us
Boule Diagnostics AB (publ) is a global company consisting of two business segments, Diagnostics and OEM CDS. Diagnostics is specialized in near-patient, decentralized diagnostic solutions for human and veterinary applications, serving hospitals, clinics, laboratories. OEM CDS develops and delivers reliable reagent, blood controls and calibrators tailored for diagnostic companies worldwide.
With operations in Sweden, the United States, Mexico, and Russia, and a global distribution network spanning more than 100 countries, Boule combines a resilient business model with strong positions in key growth markets. In 2024, Boule reported net sales of SEK 558 million and has about 200 employees worldwide. Boule has been listed on Nasdaq Stockholm since 2011. http://www.boule.com
This information is information that Boule Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-12-30 08:30 CET.